Review Article

Influence of Inflammation on Poststroke Plasticity

Monika Liguz-Lecznar\(^1\) and Malgorzata Kossut\(^1,2\)

\(^1\) Laboratory of Neuroplasticity, Nencki Institute of Experimental Biology, Polish Academy of Science, 3 Pasteur Street, 02-093 Warsaw, Poland
\(^2\) Warsaw School of Social Science and Humanities, 19 Chodakowska Street, 03-815 Warsaw, Poland

Correspondence should be addressed to Monika Liguz-Lecznar; m.liguz@nencki.gov.pl

Received 27 November 2012; Accepted 11 January 2013

Copyright © 2013 M. Liguz-Lecznar and M. Kossut. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Age-related brain injuries including stroke are a leading cause of morbidity and mental disability worldwide. Most patients who survive stroke experience some degree of recovery. The restoration of lost functions can be explained by neuronal plasticity, understood as brain ability to reorganize and remodel itself in response to changed environmental requirements. However, stroke triggers a cascade of events which may prevent the normal development of the plastic changes. One of them may be inflammatory response initiated immediately after stroke, which has been found to contribute to neuronal injury. Some recent evidence though has suggested that inflammatory reaction can be also neuroprotective. This paper attempts to discuss the influence of poststroke inflammatory response on brain plasticity and stroke outcome. We also describe the recent anti-inflammatory strategies that have been effective for recovery in experimental stroke.

1. Introduction

Ischemic stroke results from two main pathological processes: a loss of oxygen and an interruption of glucose supply to a particular brain region. The collapse of energy provision leads to the dysfunction of ionic pumps, loss of membrane potential, and uncontrolled release of neurotransmitters. The consequence of those processes is the increase of intracellular calcium concentrations that, among many deleterious effects, result in the generation of free radicals, leading to disintegration of cell membranes and subsequent neuronal death in the core of infarction [1]. Necrosis in the center of infarction can start a few minutes after stroke and is followed by peri-infarct depolarizations, excitotoxicity, edema, and oxidative stress [2].

The more delayed processes accompanying stroke are inflammation and apoptosis. They are initiated several hours after ischemic attack and can persist even for several weeks [3].

Although a great progress has been made in understanding the cellular and molecular mechanisms of ischemic tissue damage, the only approved therapy is still thrombolysis achieved by intravenous administration of recombinant tissue plasminogen activator (tPA). Unfortunately, short therapeutic window for this therapy strongly limits the fraction of patient that can benefit from the treatment. Moreover, stroke induces a complex cascade of inflammatory response which contributes to the posts ischemic damage. The complex nature of phenomena after ischemic event hampers a successful design of effective therapeutic strategies (Figure 1).

Especially desirable are neuroprotective and prorregenerative treatments that could support the poststroke recovery. Several animal and human studies revealed that recovery after stroke and restoration of lost functions can be explained by neuronal plasticity, understood as brain ability to reorganize and remodel itself in response to changed environmental requirements [4–6]. Duncan has pointed to the careful defying of recovery, since more stroke survivors will achieve the positive outcome if recovery is defined in terms of disability than if impairments are used to define it [6].

Ischemic stroke triggers an inflammatory cascade via the activation of different molecular mediators. Failure of
delivery of energy metabolites leads to the accumulation of glutamate in extracellular space and excitotoxicity. Within the ischemic tissue a reactive oxygen species are generated and integration of brain-blood barrier is disrupted. Microglia are the first nonneuronal cells that respond to injury, and they are the main source of proinflammatory cytokines and chemokines. Their release results in the activation of resident microglia, upregulation of cell adhesion molecules, and mobilization of leukocytes. Increased oxidative stress and cytokine activation contribute to further exacerbation of the inflammatory process including the upregulation of matrix metalloproteinases (MMPs) from astrocytes and microglia that leads to blood-brain barrier (BBB) dysfunction and finally to neuronal cell death. Aging, which is a risk factor for the stroke, further exacerbates the neuroinflammatory pathways and in the same time decreases the potential of neurons for functional plasticity in healthy brain. Since the poststroke recovery and restoration of lost functions can be explained by neuronal plasticity, the diminished ability of reorganization may be the significant factor resulting in poorer functional outcome in elderly stroke patients.

2. Plasticity after Stroke: Enhanced or Impaired?

Despite the nonpermissive environment, in most cases of stroke-induced brain damage, some degree of spontaneous recovery can be observed within the first posttrauma months [7, 8]. To address this issue we investigated the spontaneous plasticity of cortical somatosensory representations following a focal photothrombotic unilateral stroke in the barrel cortex of rats to define the reorganization of cortical activity which correlated with poststroke compensatory plasticity. An evolution of the pattern of brain activation in response to stimulation of vibrissae projecting to the damaged barrel cortex was observed through 2 poststroke months. After general loss of metabolic activation in the lesioned hemisphere, we observed a significant increase of activation in the ipsilesional somatosensory areas. Finally, two months after the stroke, the enhanced activation of ipsilateral hemisphere disappeared and in the stroked hemisphere three sites in the undamaged regions of somatosensory cortex: anterior vibriissae, front paw, and hind paw representations, responded to vibrissal input. The appearance of new activation foci correlated with the full recovery of the behavioral functions measured with the gap-crossing test [9]. Similar pattern of changes was reported in human longitudinal studies of poststroke recovery [10]. The studies of Nudo et al. [11] demonstrated that in adult primates cortex the rehabilitation is important for plasticity leading to the reconstruction of injured cortical motor representation. Thus, the poststroke plasticity is use dependent. It has been attributed to activation of existing, but weak connections, axonal outgrowth, dendritic arborizations, and synaptogenesis: phenomena that accompany functional restoration of neuronal networks [5, 10, 12, 13]. Experimental stroke in rats was shown to induce a process of axonal sprouting in peri-infarct tissue [14, 15] that is accompanied by a unique expression pattern of growth-promoting genes and elimination of chondroitin sulfate proteoglycans, which limit axonal sprouting in glial scar adjacent to infarct [16]. Rapid changes in the number length and turnover of dendritic spines in mice can be observed as soon as few minutes after focal ischemia [17], but that initial loss is then followed by dynamic reestablishment of spine synapses [18, 19]. Also it has been shown in experimental stroke [20] and confirmed in human [21] that cortical responsiveness to the impaired extremity after initial loss is gradually restored predominantly in peri-infarct, but also in more distant regions and homotopic sites in the intact hemisphere.

In addition to neuronal death in the ischemic core, the postischemic loss of function is determined by not
only the dysfunction of cells in the surrounding penumbra region, but also loss of connections and altered neuronal transmission in more remote brain areas [10, 22, 23]. Thus, compensation for a functional loss should include unmasking the silent pathways and synapses or recruitment of alternative pathways. The second would require axonal sprouting and formations of synapses de novo. Several animal studies demonstrated a long-range sprouting of axons in several different brain connections, including corticocortical, corticospinal, and corticalubular projections after focal stroke [24–26]. In human, recent studies that used diffusion tensor-imaging technique (DTI) have demonstrated that changes in white matter integrity may be important for recovery of motor function after ischemia [27, 28]. A study in aphasic patients, since aphasia often occurs as the result of stroke, found plasticity of arcuate fasciculus after long-lasting speech therapy [29].

Glial cells can also contribute to poststroke recovery. Astrocytes that infiltrate the area surrounding the ischemic core also support the neuronal regeneration through delivery of trophic factors and lipids. They form the glial scar that embraces the infarction and restricts the range of inflammation [30]. It was shown in different stroke models that in the peri-infarct area the chondroitin sulfate proteoglycans, such as aggrecan, phosphacan, and versican, are reduced as are reduced perineuronal nets formed by those proteoglycans [16, 31]. Such changes may promote plastic modification of neuronal connectivity.

Regardless of the abovementioned observations suggesting the facilitation of plasticity after stroke, other studies brought contradictory results. Using [14C]2-deoxyglucose autoradiography Dietrich and colleagues have described persisting for two months significant decrease of cerebral metabolic rates of glucose throughout the traumatized hemisphere in rats as soon as 4 h after traumatic brain injury. The change was most pronounced in regions adjacent to the infarct, but significant decreases were also seen in more remote brain areas. The observed inability to activate the particular cortical circuit testifies to the postransient circuit dysfunction [32, 33]. In experiments designed specially to test plasticity after stroke in peri-infarct cortex, we examined plastic changes in the cortical representation of vibrissae, induced by sensory manipulation. Of the five rows of facial vibrissae, one was left intact and the others were shaved. In rats with unilateral focal photothrombotic stroke neighboring the whisker representation in the barrel cortex, we have observed (with 2DG autoradiography) the impairment of sensory deprivation-induced plasticity of functional vibrissae representation [34, 35] (Figure 2). This effect was replicated on mice with photothrombotic stroke (Liguz-Leczynar, unpublished data). Similarly, Greifzu and colleagues observed that a photothrombotic lesion outside the visual cortex prevented visual plasticity in mice. One week after stroke and monocular deprivation, the animals showed neither improvement of visual acuity and contrast sensitivity of the opened eye nor an ocular dominance shift toward this eye in the lesioned hemisphere [36]. Thus both in somatosensory cortex and in visual cortex no facilitating effect of stroke upon plasticity was observed. On the contrary, the effects of stroke were detrimental for experience-dependent plastic changes. In human, Cramer and Seitz [37] have used fMRI and measurements of blood oxygenation level-dependent (BOLD) method to show that the activation of peri-infarct tissue is reduced in patients with stroke compared with healthy controls.

Those observations seemed to be inconsistent with some results of receptor binding and electrophysiological studies that reported the increase of NMDA receptor binding [38], reduced inhibition [6, 39], and increased long-term potentiation in the surround of experimentally induced focal cortical infarction [40], which were in line with the poststroke plasticity facilitation concept. The discrepancies may be linked to the metabolic and physiological events taking place shortly after stroke. Edema, spreading depression, and inhibition of ionic pumps that accompany the first poststroke period are unlikely to support plastic changes [41]. Moreover, for at least several days after MCAO stroke in mice a protein synthesis impairment was observed [42], which can disturb the translation higher brain activity and long-term potentiation into the durable synaptic modification underlying plasticity of cortical representations. Also plasticity-limiting factors, such as outgrowth inhibitors (MAG, NoGO), extracellular matrix proteins (tenascin, chondroitin sulfate proteoglycans), and matrix metalloproteinases (MMPs) are triggered by brain injury and experimental stroke [43–45]. In our experiments the injection of the broad-spectrum MMPs inhibitor immediately before ischemia prevented the poststroke impairment of use-dependent plasticity in somatosensory cortex of mice [46] (Figure 2).

Deliberating the issue of plasticity after brain injury it has to be emphasized that mechanisms of injury in brain trauma and those observed in ischemia differ substantially regarding inflammation range and distribution, cell death dynamics, and free radical damage. Thus, the tissue environments induced by those two pathologies will generate distinct regions permissive for axonal sprouting and regeneration [24]. As we have shown, use-dependent plasticity is not facilitated by the stroke. On the contrary, stroke triggers a cascade of changes which may prevent the normal development of the plastic change. One of them may be the inflammatory reaction.

In rats and mice a plastic change in functional cortical somatosensory representation can be evoked by trimming all the rows of vibrissae except one. The cortical representation of this spared row of whiskers enlarges rapidly over neighboring cortex deprived of sensory input. We have described the impairment of experience-dependent plasticity in somatosensory cortex neighboring the infarct in mouse and rat. Plasticity was induced using deprivation-based protocol, in which all but one row of whiskers were trimmed unilaterally. Spared whiskers were contralateral to infarct. Deprivation-induced plasticity that started immediately after stroke did not evoke the expansion of spared whiskers representation (red color on the scheme) which was visible in control mice and rats after 7 and 30 days of deprivation, respectively.

In mice with stroke, single presischemic injection of matrix metalloproteinases inhibitor (FN-439) prevented the
stroke-induced plasticity impairment. The enlargement of spared row of whiskers representation was similar to control animals [46].

In rats with ischemic stroke, daily injections of ibuprofen (nonselective cyclooxygenases inhibitor) both doses (10 and 20 mg/kg) partially reestablished the poststroke plasticity. Lower-dose treatment resulted in increase of spared row representation but however did not differ from stroke group. Injection of higher ibuprofen dose had stronger effect ad resulted in significantly higher expansion of spared row representation. Prorogation of deprivation onset in relation to stroke has similar effect on ibuprofen treatment. After one-week delay spared row representation did not differ significantly from rats deprived immediately after ischemia. Postponement of the deprivation onset to 28 days after stroke resulted in significantly larger expansion of spared row representation than in stroke group. However, it was smaller than in healthy animals [35].

3. Inflammation a Friend or an Enemy?

Stroke is known to be associated with inflammation. It is followed by acute and prolonged inflammatory response including the activation of glial cells, production of inflammatory cytokines, and infiltration of monocytes into the brain. It has been shown that these ischemic events contribute to brain injury, but, on the other hand, inflammatory cells can participate in tissue remodeling following brain damage [47]. The matter of detrimental versus beneficial influence of inflammatory response on brain function and recovery after stroke is extensively discussed [48]. There is abundant evidence that poststroke immune response embraces the releasing of number of destructive mediators including proinflammatory cytokines, matrix metalloproteinases, and reactive oxygen species [49], and many studies have reported beneficial effects of immunosuppressive manipulations on the stroke outcome (Table 1).

The treatment with a tetracyclic antibiotic minocycline was shown to be successful neuroprotective agent. Recent paper by Liebigt et al. [50] has shown that, in rats, poststroke application of minocycline and indomethacin, combined with rehabilitative training, produces improved functional recovery compared to training alone. Through an anti-inflammatory action, reduction of microglial activation, matrix metalloproteinase activity, and nitric oxide production, minocycline was shown to reduce the infarct size and glutamate-induced cell death as well as to improve the functional recovery after stroke [51–53]. Several recent studies have reported improved functional outcome in minocycline-treated patients and suggested that it could be used with
tissue plasminogen activator in treatment of acute ischemic stroke [54–56]. The therapy using sphingosine 1-phosphate receptor agonist (FTY720), which decreases the number of infiltrating T lymphocytes, was able to reduce the infarct volume, rescue neuronal death, and improve neurological score after MCAO in rats [57]. One of the recent therapies for experimental stroke has been intravenous immunoglobulin (IVIG) treatment which has the potential to inhibit multiple components of inflammation. The administration of IVIG to mice subjected to experimental MCAO stroke almost entirely eliminated mortality and reduced the amount of brain damage [58]. More precise pharmacological tools allow to target and inhibit specific factors in the complement cascade which influence the adhesion molecule upregulation, neutrophil chemotaxis, platelet activation, and generation of ROS, and it was shown that inhibition of specific complement components prevented tissue injury after stroke and reduced the infarct volume [59].

Other type of poststroke interventions comprises the anticytokine strategies, since experimental data indicate strongly that in animals and humans levels of several inflammatory cytokines, that is, IL-1, IL-6, or TNF-α are associated with the stroke severity and that the mitigation of inflammatory response attenuates the poststroke tissue damage [60–62]. IL-1 is not directly toxic to healthy neurons but contributes to neuronal death indirectly through actions on astrocytes and brain endothelial cells. It activates astrocytes leading to production of other inflammatory mediators like tumor necrosis factor alpha (TNF-α). The neuromodulatory effect of IL-1 is dose dependent: lower concentrations induce depolarization and higher hyperpolarization leading to the inhibition of synaptic transmission. IL-1 regulates phosphorylation of NMDA receptor and calcium influx and mediates excitotoxicity [63]. Since IL-1 appears to play little if any role in normal brain function, the IL-1 cytokine system seems to be particularly attractive therapeutic target in stroke. Applying interleukin-1 receptor antagonist in animal stroke models Loddick and Rothwell achieved neuroprotective effect in cerebral ischemia in rat [64]. Also IL-1 deficiency leads to reduced ischemic injury [65]. Moreover, it was shown that a single subcutaneous injection of IL-IRA was enough to reduce damage caused by MCAO in rats by 33%. IL-IRA penetrated brain tissue exclusively in areas of blood-brain barrier, rapidly reached salvageable brain tissue, and was able to confer its protective actions both peripherally and centrally [66].

TNF-α can be synthesized in CNS by resident macrophages, astrocytes, and microglia and is one of the central mediators of tissue inflammation that has been implicated in the pathogenesis of many neurological conditions. The activation of its receptor initiates signals leading to neuronal apoptosis. This cytokine seems to be proinflammatory during the acute phase of CNS inflammatory responses, but immunosuppressive during the chronic phase. TNFα stimulates expression of IL-1 and can induce also IL-6 [67]. Intraventricular injection of TNF-α enlarged infarct volume and brain edema after MCA occlusion in rats, whereas the injection of antibodies TNF-α reduced brain injury [62]. It was also shown that after MCAO mice deficient in TNF or functional CD95L, which belongs to the tumor necrosis factor (TNF) protein family, are protected against brain ischemia having reduced neuronal death and smaller degree of locomotor impairment [68]. Treatment with recombinant human TNF 55kDa receptor reduced tissue damage and improved neurological symptoms after stroke in rats [69].

Interleukin 6 is a cytokine that controls an inflammatory response between blood cells, vascular endothelium, and brain parenchyma and can induce the synthesis of some chemokines and cell adhesion molecules that, together with blood-brain barrier leakage, can enable leukocyte infiltration. In the brain parenchyma, IL-6 activates gliosis and leukocyte activation [70]. Many investigators reported the association between IL-6 and early poststroke neurological worsening, proving that the level of IL-6 in plasma was highly correlated with infarct volume and positive association between IL-6 and the strength of the acute-phase response, which is considered to be a predictor of poor short-term clinical outcome [61, 71, 72].

In order to establish if the inflammatory processes are behind the impairment of plasticity observed after stroke, we examined the effects of chronic administration of ibuprofen, a nonselective inhibitor of cyclooxygenase 2 (an enzyme involved in postischemic tissue damage), on poststroke experience-dependent plasticity in somatosensory cortex. While in untreated rats photothrombotic stroke impaired this type of plasticity, in animals with daily doses of ibuprofen, we observed reestablishment of the modification of vibrissal cortical representation [35]. We also demonstrated that the level of cyclooxygenase 2, elevated after stroke, was reduced by the ibuprofen treatment. However, no neuroprotective effects were observed: the extent of stroke-induced damage was unchanged. Preliminary data of our experiments showed, moreover, that administration of soluble receptor of TNF-α after focal ischemia in mice has beneficial effect on functional plasticity in somatosensory cortex (Liguz-Leczynar, unpublished data). Ibuprofen treatment was also shown to be effective in restoration of the enhancement of vision after monocular deprivation that was abolished in stroked mice [36]. Thus, lowering of inflammatory reaction after stroke makes it possible to rescue cortical plasticity. Overcoming postischemic inflammation may be an important part of treatment leading to functional recovery.

However, there is also evidence that contradicts the beneficial effects of immunosuppression [73], proving that the effect of particular components of the inflammatory cascade can be beneficial depending on the stage of tissue injury, the magnitude of the response, and whether the inflammatory component also activates neuroprotective pathways [74–76]. Development of therapeutic strategies based on the inhibition of TNF-α activity is complicated by its dual role. In mice that lacked both receptors for TNF-α: TNFRI and TNFRII which have been subjected to MCAO the infarct area and oxidative stress were larger than in wild-type controls, suggesting the cytoprotective role of TNF [74]. Also IL-6 as a pleiotropic mediator can potentially exert detrimental or beneficial effects following ischemia, as the administration of antimouse IL-6 receptor monoclonal antibody or knocking out IL-6 gene increased infarct size [70, 77]. Moreover, chronic
Table 1: Examples of anti-inflammatory strategies effective in experimental stroke.

| Target mediator in inflammatory cascade | Therapeutic intervention | Outcome | Literature examples |
|----------------------------------------|--------------------------|---------|---------------------|
| General inflammation                   | Minocycline              | Attenuation of ischemic deficits are inhibition of apoptotic neuronal cell death after MCAO. Better outcome from stroke in patients | [54–56, 78] |
|                                        | Intravenous immunoglobulin therapy | Elimination of mortality and reduction of brain damage after MCAO in mice | [58, 59] |
| Complement inhibition                  | Cobra venom factor (CVF) | Reduced infarct and atrophy are improved clinical outcome | [79, 80] |
|                                        | Cl inhibition: Cl-INH    | Neuroprotection | [81] |
|                                        | C3 inhibition: sCRI, C3 KO | Reduced infarct volume and neurological deficit score | [82, 83] |
|                                        | C5 inhibition: C5 KO     | Improvement of functional outcome, reduced brain damage | [58] |
| Leukocytes                             | Neutrophil inhibitory factor | Neuroprotection after focal ischemia in rats and reduction of the number of infiltrated neutrophils and infarct volume | [84, 85] |
| Lymphocytes T                          | Sphingosine 1-phosphate receptor agonist FTY720 (Fingolimod) | Reduction of infarct volume and cell death and improvement of neurological score after MCAO in rats | [57, 86, 87] |
| Prostaglandins                         | Cyclooxygenase pathway: Ibuprofen | Restoration of plasticity in visual and somatosensory cortex after photothrombotic stroke in mice without the neuroprotective effect | [35, 36] |
|                                        | COX-2 KO                 | Reduction in the brain injury after MCAO in mice | [88] |
| Cytokines                              | IL-1:                    | Administration of human interleukin-1 receptor antagonist reduced damage caused by MCAO in rats | [64, 66] |
|                                        | IL-1 receptor antagonist | 70% reduction of infarct volume after MCAO | [65, 89, 90] |
|                                        | IL-1 KO                  | Reduced brain damage and increased neuronal survival after ligation of right common carotid artery in mice | [91] |
|                                        | IL-1R1 null mice         | Blocking endogenous TNF-alpha reduced focal ischemic brain injury in mice and rats after MCAO | [62, 92] |
|                                        | Anti-TNF antibodies      | Reduction of stroke volume, neural deficits, extent of microglial cell activation, and apoptotic cell death after MCAO in mice | [93, 94] |
|                                        | TNF decoy receptor       | Reducing the size of infarct after MCAO in mice | [75] |

injection of recombinant IL-6 into the lateral ventricle of prevented the postischemic learning disabilities and delayed neuronal loss and in other study reduced ischemic brain damage after MCAO [70].

### 4. Conclusions

Recovery after stroke is complex phenomenon. Many interventions have been developed to support the poststroke recovery and an increasing number of randomized controlled trials and systematic reviews are in progress. Spontaneous neuroplasticity triggered after stroke by behavioral demand of coordinated movements and the need for cognitive control gradually reorganizes brain connections. Injury causes the activation of numerous factors that impede plasticity, among them are several chemokines and cytokines involved in inflammatory reaction. Treatments inhibiting cyclooxygenases enhance poststroke plasticity. However, some elements of inflammatory cascade can improve recovery. Since postischemic inflammation is associated not only with ischemic damage but also with the repair of injured brain tissue, the most important aspect of therapies targeting the immune system will be to regulate the balance between the neurotoxic and neuroprotective effects of inflammatory state components.

### Acknowledgments

The authors were supported by statutable funds of Nencki Institute of experimental Biology and by Polish National Science Center Grant N N401 098739.
somatosensory activation,” American Journal of Physiology, vol. 279, no. 3, pp. H924–H931, 2000.

[34] J. Jablonka and M. Kossut, “Focal stroke in the barrel cortex of rats enhances ipsilateral response to vibrisal input,” Acta Neurobiologiae Experimentalis, vol. 66, no. 3, pp. 261–266, 2006.

[35] J. A. Jablonka, M. Kossut, O. W. Witte, and M. Liguz-Lecznar, “Experience-dependent brain plasticity after stroke: effect of ibuprofen and poststroke delay,” European Journal of Neuroscience, vol. 36, pp. 2632–2639, 2012.

[36] F. Greifzu, S. Schmidt, K. F. Schmidt, K. Kreikemeier, and O. W. Witte, “Global impairment and therapeutic restoration of visual plasticity mechanisms after a localized cortical stroke,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, pp. 15450–15455, 2011.

[37] S. C. Cramer and R. J. Seitz, “Imaging functional recovery from stroke,” Handbook of Clinical Neurology, vol. 94, pp. 1097–1117, 2008.

[38] M. Que, K. Schiene, O. W. Witte, and K. Zilles, “Widespread up-regulation of N-methyl-D-aspartate receptors after focal photothermbotic lesion in rat brain,” Neuroscience Letters, vol. 273, no. 2, pp. 77–80, 1999.

[39] T. Neumann-Haefelin and O. W. Witte, “Perinfarct and remote excitability changes after transient middle cerebral artery occlusion,” Journal of Cerebral Blood Flow and Metabolism, vol. 20, no. 1, pp. 45–52, 2000.

[40] G. Hagemann, C. Redecker, T. Neumann-Haefelin, H. J. Freund, and O. W. Witte, “Increased long-term potentiation in the surround of experimentally induced focal cortical infarction,” Annals of Neurology, vol. 44, no. 2, pp. 255–258, 1998.

[41] K. A. Hossmann, “The hypoxic brain: insights from ischemia research,” Advances in Experimental Medicine and Biology, vol. 474, pp. 155–169, 2000.

[42] R. Hata, K. Maeda, D. Hermann, G. Mies, and K. A. Hossmann, “Evolution of brain infarction after transient focal cerebral ischemia in mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 20, no. 6, pp. 937–946, 2000.

[43] J. L. Cheatwood, A. J. Emerick, M. E. Schwab, and G. L. Kartje, “Nogo-A expression after focal ischemic stroke in the adult rat,” Stroke, vol. 39, no. 7, pp. 2091–2098, 2008.

[44] S. Li and S. T. Carmichael, “Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke,” Neurobiology of Disease, vol. 23, no. 2, pp. 362–373, 2006.

[45] L. Kaczmarek, “MMP-9 inhibitors in the brain: can old bullets shoot new targets?” Current Pharmaceutical Designs, vol. 19, no. 6, pp. 1085–1089, 2012.

[46] A. Cybulska-Klosowicz, M. Liguz-Lecznar, D. Nowicka, M. Ziemia-Nalecz, M. Kossut, and J. Skangiel-Kramska, “Matrix metalloproteinase inhibition counteracts impairment of cortical experience-dependent plasticity after photothermbotic stroke,” European Journal of Neuroscience, vol. 33, pp. 2238–2246, 2011.

[47] J. Kriz, “Inflammation in ischemic brain injury: timing is important,” Critical Reviews in Neurobiology, vol. 18, no. 1-2, pp. 145–157, 2006.

[48] R. Macrez, C. Ali, O. Toutirais et al., “Stroke and the immune system: from pathophysiology to new therapeutic strategies,” The Lancet Neurology, vol. 10, pp. 471–480, 2011.

[49] Q. Wang, X. N. Tang, and M. A. Yenari, “The inflammatory response in stroke,” Journal of Neuroimmunology, vol. 184, no. 1-2, pp. 53–68, 2007.

[50] S. Liebigt, N. Schlegel, J. Oberland, O. W. Witte, C. Redecker, and S. Keiner, “Effects of rehabilitative training and anti-inflammatory treatment on functional recovery and cellular reorganization following stroke,” Experimental Neurology, vol. 233, pp. 776–782, 2012.

[51] N. Morimoto, M. Shimazawa, T. Yamashima, H. Nagai, and H. Hara, “Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage,” Brain Research, vol. 1044, no. 1, pp. 8–15, 2005.

[52] Y. C. Weng and J. Kriz, “Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia,” Experimental Neurology, vol. 204, no. 1, pp. 433–442, 2007.

[53] H. C. A. Emsley, C. J. Smith, P. J. Tyrrell, and S. J. Hopkins, “Inflammation in acute ischemic stroke and its relevance to stroke critical care,” Neurocritical Care, vol. 9, no. 1, pp. 125–138, 2008.

[54] M. V. Padma Srivastava, A. Bhasin, R. Bhatia et al., “Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled trial,” Neurology India, vol. 60, pp. 23–28, 2012.

[55] S. C. Fagan, L. E. Cronic, and D. C. Hess, “Minocycline development for acute ischemic stroke,” Translational Stroke Research, vol. 2, no. 2, pp. 202–208, 2011.

[56] S. C. Fagan, J. L. Waller, F. T. Nichols et al., “Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study,” Stroke, vol. 41, no. 10, pp. 2283–2287, 2010.

[57] Y. Hasegawa, H. Suzuki, T. Sozen, W. Rolland, and J. H. Zhang, “Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats,” Stroke, vol. 41, no. 2, pp. 368–374, 2010.

[58] T. V. Arumugam, S. C. Tang, J. D. Lathia et al., “Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 35, pp. 14104–14109, 2007.

[59] T. V. Arumugam, T. M. Woodruff, J. D. Lathia, P. K. Selvaraj, M. P. Mattson, and S. M. Taylor, “Neuroprotection in stroke by complement inhibition and immunoglobulin therapy,” Neuroscience, vol. 158, no. 3, pp. 1074–1089, 2009.

[60] N. B. Beamer, B. M. Coull, W. M. Clark, J. S. Hazel, and J. R. Silberger, “Interleukin-6 and interleukin-1 receptor antagonist in acute stroke,” Annals of Neurology, vol. 37, no. 6, pp. 800–804, 1995.

[61] N. Vila, J. Castillo, A. Dávalos, and A. Chamorro, “Proinflammatory cytokines and early neurological worsening in ischemic stroke,” Stroke, vol. 31, no. 2, pp. 317–323, 2000.

[62] F. C. Barone, B. Arvin, R. F. White et al., “Tumor necrosis factor-α: a mediator of focal ischemic brain injury,” Stroke, vol. 28, no. 6, pp. 1233–1244, 1997.

[63] A. Denes, E. Pinteaux, N. J. Rothwell, and S. M. Allan, “Interleukin-1 and stroke: biomarker, harbringer of damage, and therapeutic target,” Cerebrovascular Diseases, vol. 32, pp. 517–527, 2011.

[64] S. A. Loddick and N. J. Rothwell, “Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat,” Journal of Cerebral Blood Flow and Metabolism, vol. 16, no. 5, pp. 932–940, 1996.

[65] Z. S. Vexler, X. N. Tang, and M. A. Yenari, “Inflammation in adult and neonatal stroke,” Clinical Neuroscience Research, vol. 6, no. 5, pp. 293–313, 2006.
[66] A. D. Greenhalgh, J. Galea, A. Dénès, P. J. Tyrrell, and N. J. Rothwell, “Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection,” British Journal of Pharmacology, vol. 160, no. 1, pp. 153–159, 2010.

[67] S. M. Lucas, N. J. Rothwell, and R. M. Gibson, “The role of inflammation in CNS injury and disease,” British Journal of Pharmacology, vol. 147, no. 1, pp. S232–S240, 2006.

[68] A. Martin-Villalba, M. Hahne, S. Kleber et al., “Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke,” Cell Death and Differentiation, vol. 8, no. 7, pp. 679–686, 2001.

[69] A. L. Sirén, R. McCarron, L. Wang et al., “Proinflammatory cytokine expression contributes to brain injury provoked by chronic monocyte activation,” Molecular Medicine, vol. 7, no. 4, pp. 219–229, 2001.

[70] S. Suzuki, K. Tanaka, and N. Suzuki, “Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects,” Journal of Cerebral Blood Flow and Metabolism, vol. 29, no. 3, pp. 464–479, 2009.

[71] C. J. Smith, H. C. A. Emsley, C. M. Gavin et al., “Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome,” BMC Neurology, vol. 4, article 2, 2004.

[72] U. Waje-Andreassen, J. Krákenes, E. Ulvestad et al., “IL-6: an early marker for outcome in acute ischemic stroke,” Acta Neurologica Scandinavica, vol. 113, no. 6, pp. 360–365, 2005.

[73] M. Krans, K. R. Lees, W. Hacke, A. P. Grieve, J. M. Orgogozo, and G. A. Ford, “Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke,” Stroke, vol. 34, no. 11, pp. 2543–2548, 2003.

[74] A. J. Bruce, W. Boling, M. S. Kindy et al., “Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors,” Nature Medicine, vol. 2, no. 7, pp. 788–794, 1996.

[75] H. Nawashiro, D. Martin, and J. M. Hallenbeck, “Neuroprotective effects of TNF binding protein in focal cerebral ischemia,” Brain Research, vol. 778, no. 2, pp. 265–271, 1997.

[76] W. Zhang and D. Stanimirovic, “Current and future therapeutic strategies to target inflammation in stroke,” Curr Drug Targets Inflamm Allergy, vol. 1, no. 2, pp. 151–166, 2002.

[77] T. Yamashita, K. Sawamoto, S. Suzuki et al., “Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons,” Journal of Neurochemistry, vol. 94, no. 2, pp. 459–468, 2005.

[78] L. Xu, S. C. Fagan, J. L. Waller et al., “Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats,” BMC Neurology, vol. 4, article 7, 2004.

[79] E. Figueroa, L. E. Gordon, P. W. Feldhoff, and H. A. Lassiter, “The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats,” Neuroscience Letters, vol. 380, no. 1-2, pp. 48–53, 2005.

[80] U. S. Vasthare, F. C. Barone, H. M. Sarau et al., “Complement depletion improves neurological function in cerebral ischemia,” Brain Research Bulletin, vol. 45, no. 4, pp. 413–419, 1998.

[81] N. Heydenreich, M. W. Nolte, E. Gob et al., “Cl-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms,” Stroke, vol. 43, pp. 2457–2467, 2012.